Klinikum Worms gGmbH

The cardiovascular research at Klinikum Worms gGmbH addresses patients with acute coronary syndrome and atrial fibrillation, aiming to test new oral anticoagulants for reducing heart attacks, strokes, and related complications.

• Evaluation of novel anticoagulant agents compared with standard therapy
• Assessment of major adverse cardiac events (MACE) reduction
• Safety profiling of bleeding risk versus established drugs
• Prevention of stroke and systemic embolism in high‑risk atrial fibrillation
• Comparative effectiveness of milvexian and asundexian

The site’s team of seven investigators collaborates closely to generate robust data that could shape future treatment guidelines.

In the neoplasms portfolio, Klinikum Worms gGmbH focuses on ER+/HER2- early breast cancer and HER2/neu positive breast cancer, exploring innovative therapies to lower recurrence after surgery and standard adjuvant treatment.

• Immunotherapeutic peptide vaccine GLSI-100 in HER2‑positive disease
• Oral selective estrogen degrader camizestrant with or without abemaciclib
• Strategies to improve disease‑free survival in high‑risk patients
• Integration of novel agents into endocrine therapy regimens
• Evaluation of residual disease response after neoadjuvant therapy

These studies are conducted by a multidisciplinary team aiming to provide new options for women battling breast cancer.